

1973. Sulphasalazine

RCT/Sulphasalazine/UC/ Maintain

Randomized double-blind controlled trial.
Patients with a ulcerative colitis who were maintained on sulphasalazine for at least 1 year were randomized to continue sulphasalazine 2gr/day vs placebo.
All were in clinical and endoscopic and histologic remission.

Primary endpoints: Relapse rate within 6 months.

Results: N=64

- Relapse rates within 6 months: 12.1% Salazopyrine vs 54.8% placebo, $p < 0.001$.
- These differences remain significant if length of previous maintenance therapy with sulphasalazine was separated into 1-3 years or >3 years, $p = 0.038$

Conclusion:

maintenance treatment of ulcerative colitis with sulphasalazine should be continued indefinitely unless contraindicated by side effects.

A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphasalazine (Salazopyrin)




Fig 1 Results for the whole series.

